Skip to content
Dose Brief
Menu
No. 539 here · Grade C

Oak review

A provider that advertises flat, all-doses-one-price GLP-1 care — with nine different starting figures live at once, a term attached to none of them, and a Terms page that contradicts the two things its marketing promises loudest.

Visit Oak Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the score.
Semaglutide
$250/mo (one flat rate at every dose), read on its order form the afternoon of 15 August; it showed $200/mo that morning
Tirzepatide
$300/mo (one flat rate at every dose), read on its order form the afternoon of 15 August; it showed $250/mo that morning
Coverage
Coverage not published
Brand-name
Compounded only

Prices read from Oak's own site on . Providers change pricing without notice — check the current figure before you buy.

On the trackerNewnew to the tracker, no prior reading— Re-read twice on 15 August 2026 with a real browser and no form input, and the figures MOVED BETWEEN THE TWO READS. In the morning its order form showed $200/mo for compounded semaglutide and $250 for tirzepatide; that afternoon, same URL, same entry path, browser storage cleared as a control, it showed $250 and $300 with the strike-throughs gone and every brand line $100 higher. What is stable is WHERE the price is: on the first screen of its order form, before a single question. The tracker previously carried no figure because the ladder was believed to be behind a 29-question intake — it is not, it is in front of it. What remains true is that Oak advertises nine different "starting" prices at once — $119, $133, $160, $167, $180, $185, $190, $199 and $250 — attaches a term to none, and that its headline "$133 / $199" is the three-month prepay under code OAKSAVE200, billed upfront.

The scorecard

Oak scored on our six Brief Score factors. See the methodology.

Price Stability38/100
Supply Reliability44/100
Transparency34/100
Access Breadth52/100
Clinical Oversight44/100
Track Record50/100

Oak in depth

Oak advertises one idea above all others — "One price · All dosages" — and the trouble is finding out what that price is. Nine different "starting" figures were live on its site simultaneously when we read it: $119, $133, $160, $167, $180, $185, $190, $199 and $250. Not one page attaches a term to any of them.

What its order form actually charged, read on the afternoon of August 8, 2026, was $250 a month for semaglutide and $300 for tirzepatide, flat at every dose. That same morning the form showed $200 and $250. So the figure moved within a single day, and none of the nine numbers Oak markets is the one it was charging on either reading. Anyone comparing Oak on an advertised price is comparing something the checkout does not honor.

The two cheapest of those figures, $119 and $185, appear only beside a "$200 off — new patient offer", and Oak's own affiliate material describes the structure as a first-order discount rather than a standing rate. Its marketing and its contract also disagree on the point the marketing makes loudest: three pages say "Membership Fees: None" and "No subscriptions", while the Terms describe something else.

We could not confirm the flat-dose claim either, and it is the claim the whole pitch rests on. Oak says "All doses are the same price"; our reading of its own checkout copy did not bear that out cleanly enough to state as fact. If flat dosing is why you are considering Oak, get it confirmed in writing before you pay.

There are real positives. The 29-question health intake is a genuine clinical screen rather than the two-question formality several providers here use. There is a true non-injectable route — sublingual drops and tablets sold alongside the injections, with oral tirzepatide itemized separately on its employer pages. Cancellation is self-serve and stops future renewals. And Oak is clean against the FDA warning-letter index under its brand, its domain and all four operating names its own documents use, screened August 8, 2026 with a passing positive control.

Four things a reader should know before starting. Oak's own documents name three different operating entities. Neither the dispensing pharmacy nor any prescriber is named — only "Oak's contracted pharmacies" and contracted clinicians. No list of served states is published. And per its own Terms, withdrawing consent after a prescription has been issued and sent to a pharmacy does not cancel or reverse that prescription.

What we like

  • Flat dose pricing is Oak's own headline claim — "One price · All dosages", "All doses are the same price" — which, if it holds, means a 0.25 mg starter pays the same as someone at 2.4 mg, the single most useful promise a provider can make to anyone who will titrate
  • A genuine non-injectable route: /weightloss sells sublingual drops and tablets alongside the injections, and /employers itemises oral tirzepatide separately, so readers who will not inject have somewhere to go
  • Both molecules are offered, and an employer lane exists for readers whose access might come through work rather than cash-pay
  • A 29-question health intake is a real clinical screen rather than the two-question formality several providers in this ranking use
  • Cancellation is self-serve, through the prescription page or by deleting the account, and stops future renewals
  • Clean against FDA's warning-letter index under the brand, the domain and all four operating names its own documents use, screened 8 August 2026 with a passing positive control

The caveats

  • Nine different "starting" figures are live on the site simultaneously — $119, $133, $160, $167, $180, $185, $190, $199 and $250 — and not one page attaches a term or a billing cadence to any of them, so there is no number on this provider a reader can plan around
  • The two cheapest of those, $119 and $185, appear only beside a "$200 off — new patient offer", and Oak's own affiliate page spells the structure out as "$50 off your first month, $200 off 3-months" — a three-month package discount. Its own undiscounted floors are $190/month and $167/mo
  • Its marketing and its contract disagree on the two things the marketing promises loudest. Three pages say "Membership Fees: None" and "No subscriptions"; the Terms say patients are charged a membership fee for a provider consult, and that most prescriptions are configured as a subscription that renews on a recurring basis against the card on file
  • We could not confirm the flat-dose claim. Oak advertises "All doses are the same price", while this provider's reading of its checkout copy on 7 August 2026 recorded the opposite — that each dose step costs roughly $50 to $75 more. Treat the flat claim as Oak's, unverified
  • Its advertising and its order form disagree: none of the nine "starting" figures Oak markets is the $200/$250 it actually charges, so anyone comparing it on the advertised numbers is comparing against a price it does not offer
  • Its own documents name three different operating entities — Oak Longevity Holdings Corp, Leaf Longevity Holdings Corp DBA Oak Longevity, and OAKLOVESYOU LLC — with the privacy policy listing Canada as its country
  • Neither the dispensing pharmacy nor any prescriber is named: only "Oak's contracted pharmacies" and "independent licensed physicians and nurse practitioners contracted through Oak's medical group partners", with no NPI published anywhere
  • No list of states served is published; the consent language says only "if and when permitted by state law"
  • The link we publish lands mid-funnel, at step 1 of 5, on an Oak-versus-competitors comparison table rather than a homepage — so the first prices a reader sees are a marketing claim with no term attached rather than anything they can buy
  • Withdrawing consent after a prescription has been issued and sent to a pharmacy does not cancel or reverse that prescription, per Oak's own Terms

The brief

Best for: Readers weighing Oak specifically who want to know what it does and does not publish before handing over 29 questions' worth of medical history — not readers trying to compare a price today. A provider that advertises flat, all-doses-one-price GLP-1 care — with nine different starting figures live at once, a term attached to none of them, and a Terms page that contradicts the two things its marketing promises loudest.

Ranked #539 of 546 providers we reviewed — see our #1 pick, CoreAge Rx, for comparison.

Visit Oak

Before you decide

The questions readers ask next after reading about Oak.

Closest here

The providers scoring nearest Oak — the realistic shortlist if you're weighing it.

Weighing Oak against one provider in particular? There is a full head-to-head with our top-ranked pick in CoreAge Rx vs Oak, and every provider that outranks it is listed on the Oak alternatives ranking.

More providers we track (24)

515 more are filed too — see every provider we track, ranked.

Pricing, states and verification reflect Oak's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on Oak's site. Not medical advice; see our disclosure.

← Back to all rankings